Ouroboros Group

Dequity Funding is a hybrid capital structure designed to combine the upside participation of equity with the contractual protections of debt. Ouroboros argues that traditional venture models force premature scaling while buyouts rely on leverage that can constrain long-term growth. The Dequity model adapts to a company's lifecycle stage, aiming to align founder incentives with patient capital deployment.

No. Ouroboros Group has not publicly disclosed its assets under management, commitment sizes, or total deployment to date. The firm offers no AUM figure on its website or in available public filings.

Ouroboros Family Founders Fund I, LP is the firm's primary disclosed investment vehicle. It pools capital to deploy across buyout, early-stage, growth, and venture strategies under the Dequity model. The fund's vintage, size, and investor base have not been made public.

Ouroboros lists buyout, early-stage (including seed and start-up), expansion and late-stage, growth, and general venture as its active strategies. The Dequity model is designed to apply across this spectrum, with capital solutions adapting as a company matures.

Ouroboros Group has not publicly named its founder, managing partners, or investment committee members. No principal bios or leadership profiles appear on the firm's website or in available public records.

The firm's stated target is businesses that enhance community wellness and improve quality-adjusted life years, which maps broadly to healthcare services, preventive health, and social-impact-aligned enterprises. No more granular sector exclusions or additional vertical focuses have been publicly confirmed.

No portfolio companies, co-investments, or realized exits have been publicly confirmed by Ouroboros Group. The firm's track record remains entirely undisclosed as of mid-2026.